Deutsch English Français

Contact

EP0948614

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP0948614

EP0948614 - NOVEL EXPRESSION VECTORS CONTAINING ACCESSORY MOLECULE LIGAND GENES AND THEIR USE FOR IMMUNOMODULATION AND TREATMENT OF MALIGNANCIES AND AUTOIMMUNE DISEASE [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 20.11.2009 Database last updated on 12.07.2024
Most recent event Tooltip	20.05.2011	Lapse of the patent in a contracting state New state(s): GR	published on 22.06.2011 [2011/25]
Applicant(s)	For all designated states The Regents of the University of California 1111 Franklin Street, 12th Floor Oakland, CA 94607 / US
	[N/P]
Former [2009/42]	For all designated states The Regents Of The University Of California 1111 Franklin Street, 5th Floor Oakland, CA 94607-5200 / US
Former [2009/03]	For all designated states University of California Technology Transfer Office, Mail code: 0093, 9500 Gilman Drive La Jolla, CA 92093-0093 / US
Former [1999/41]	For all designated states University Of California Technology Transfer Office, Mail code: 0093, 9500 Gilman Drive La Jolla, CA 92093-0093 / US
Inventor(s)	01 / KIPPS, Thomas, J. 13175 Caminito Mendiola San Diego, CA 92130 / US
	02 / SHARMA, Sanjai 11478 Duenda Road San Diego, CA 92127 / US
	03 / CANTWELL, Mark 3987 Nobel Drive 291 San Diego, CA 92122 / US
	[1999/42]
Former [1999/41]	01 / KIPPS, Thomas, J. 13175 Caminito Mendiola San Diego, CA 92130 / US
	02 / SHARMA, Sanjai 11478 Duenda Rd. San Diego, CA 92127 / US
	03 / CANTWELL, Mark 3987 Nobel Dr. 291eet San Diego, CA 92122 / US
Representative(s)	Viering, Jentschura & Partner mbB Patent- und Rechtsanwälte Grillparzerstraße 14 81675 München / DE
	[N/P]
Former [1999/42]	Viering, Jentschura & Partner Postfach 22 14 43 80504 München / DE
Application number, filing date	97954089.5	08.12.1997
	[1999/41]
	WO1997US22740
Priority number, date	US19960032145P	09.12.1996 Original published format: US 32145 P
	US19970982272	01.12.1997 Original published format: US 982272
	[1999/42]
Former [1999/41]	US19960321454	09.12.1996
	US19970982272	01.12.1997
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO9826061
	Date:	18.06.1998
	Language:	EN
	[1998/24]
	Type:	A2 Application without search report
	No.:	EP0948614
	Date:	13.10.1999
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 18.06.1998 takes the place of the publication of the European patent application.
	[1999/41]
	Type:	B1 Patent specification
	No.:	EP0948614
	Date:	14.01.2009
	Language:	EN
	[2009/03]
Search report(s)	International search report - published on:	EP	19.11.1998
Classification	IPC:	C12N15/12, C12N15/62, C07K14/48, C07K14/52, C07K14/525, C07K14/705, C12N15/86, A61K48/00, A61K38/17, A61K35/12	[1999/42]
	CPC:	C07K14/48 (EP,US); A61P35/00 (EP); A61P37/00 (EP); C07K14/52 (EP,US); C07K14/525 (EP,US); C07K14/5255 (EP,US); (+) C07K14/705 (EP,US); C07K14/70575 (EP,US); A61K2039/51 (EP,US); A61K48/00 (EP,US); C07K2319/00 (EP,US); C12N2799/021 (EP,US) (-)
	Former IPC [1999/41]	C12N15/00, A61K48/00
Designated contracting states	AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [1999/41]
Title	German:	EXPRESSIONSVEKTOREN DIE GENE ENTHALTEN FÜR AKZESSORISCHE MOLEKÜL-LIGANDEN UND DEREN VERWENDUNG ZUR IMMUNOMODULATION UND BEHANDLUNG VON BÖSARTIGEN TUMOREN UND AUTOIMMUNKRANKHEITEN	[1999/42]
	English:	NOVEL EXPRESSION VECTORS CONTAINING ACCESSORY MOLECULE LIGAND GENES AND THEIR USE FOR IMMUNOMODULATION AND TREATMENT OF MALIGNANCIES AND AUTOIMMUNE DISEASE	[1999/41]
	French:	NOUVEAUX VECTEURS D'EXPRESSION CONTENANT DES GENES DE LIGANDS DE MOLECULES ACCESSOIRES ET LEUR EMPLOI A DES FINS D'IMMUNOMODULATION ET DE TRAITEMENT DES TUMEURS MALIGNES ET DES MALADIES AUTOIMMUNES	[1999/41]
	Former [1999/41]	SEKRETIERTE PROTEINE UND DIE DAFÜR KODIERENDEN POLYNUKLEOTIDE
Entry into regional phase	08.07.1999	National basic fee paid
	08.07.1999	Designation fee(s) paid
	08.07.1999	Examination fee paid
Examination procedure	01.07.1998	Request for preliminary examination filed International Preliminary Examining Authority: EP
	08.07.1999	Examination requested [1999/42]
	02.03.2001	Request for accelerated examination filed
	23.01.2002	Despatch of a communication from the examining division (Time limit: M06)
	23.01.2002	Decision about request for accelerated examination - accepted: Yes
	31.07.2002	Reply to a communication from the examining division
	02.06.2004	Despatch of a communication from the examining division (Time limit: M06)
	08.12.2004	Reply to a communication from the examining division
	21.09.2005	Date of oral proceedings
	31.10.2005	Minutes of oral proceedings despatched
	15.11.2005	Despatch of communication that the application is refused, reason: substantive examination {1}
	02.03.2007	Despatch of a communication from the examining division (Time limit: M04)
	27.04.2007	Reply to a communication from the examining division
	27.11.2007	Communication of intention to grant the patent
	28.03.2008	Fee for grant paid
	28.03.2008	Fee for publishing/printing paid
Appeal following examination	16.01.2006	Appeal received No. T0472/06
	16.03.2006	Statement of grounds filed
	07.12.2006	Result of appeal procedure: remittal for grant
	07.12.2006	Date of oral proceedings
	12.12.2006	Minutes of oral proceedings despatched
Divisional application(s)	EP06125424.9 / EP1806360
	EP09164341.1 / EP2145958
	EP10184082.5 / EP2287309
Opposition(s)	15.10.2009	No opposition filed within time limit [2009/52]
Fees paid	Renewal fee
	30.12.1999	Renewal fee patent year 03
	22.12.2000	Renewal fee patent year 04
	13.12.2001	Renewal fee patent year 05
	13.12.2002	Renewal fee patent year 06
	27.11.2003	Renewal fee patent year 07
	23.12.2004	Renewal fee patent year 08
	27.12.2005	Renewal fee patent year 09
	27.12.2006	Renewal fee patent year 10
	24.12.2007	Renewal fee patent year 11
	19.11.2008	Renewal fee patent year 12
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	AT	14.01.2009
	GR	15.04.2009
	[2011/25]
Former [2010/05]	AT	14.01.2009
Cited in	International search	[X]WO9308207 (IMMUNEX CORP [US]) [X] 50-56 * example 13; claims 15-17 *;
		[A]WO9404680 (SCHERING CORP [US]) [A] 9,10,15,19,25,27,53,54,72,74,75 * page 77, line 10 - line 19 *;
		[X]WO9417196 (IMMUNEX CORP [US]) [X] 46 * See the whole document, especially claim 13. *;
		[XY]WO9514487 (UNIV AUSTRALIAN [AU], et al) [X] 1,4-10,23-38,43,44,47,67,69 * See the whole document, especially the examples and claims 8 and 12.; page 4, paragraph 1 * [Y] 3,11-19,21,22,68;
		[XY]WO9518819 (IMMUNEX CORP [US]) [X] 1,4-7,23,28-38,47-49 * page 16, line 14 - line 29 * * page 6, line 15 - line 16 * [Y] 20;
		[X]EP0675200 (MOCHIDA PHARM CO LTD [JP], et al) [X] 48,49 * See the whole document, especially the examples, and claim 21,40,41,43. *;
		[X]WO9532627 (UNIV COLORADO [US], et al) [X] 70-77 * page 19, line 22 - line 29; example 14; claims 12,16,20 * * page 14, line 10 *;
		[Y]WO9614876 (UNIV COLORADO [US], et al) [Y] 20 * See the whole document, particularly claim 23. *;
		[Y]WO9618413 (UNIV BIRMINGHAM [GB]) [Y] 3,11-19,21,22,68 * page 10, paragraph 3; claims 1-9 *;
		[X]WO9622370 (UAB RESEARCH FOUNDATION [US]) [X] 2 * page 43, line 29 - line 31 *;
		[A] - CANTWELL, M.J. ET AL., "CD95 and FAS-ligand expression and apoptosis in rheumatoid arthritis.", ARTHRITIS AND RHEUMATISM, (199609), vol. 39, no. 9, suppl., page 287, XP002066597 [A] 20,70-77 * the whole document *
		[PXT] - WIERDA, W.G. ET AL., "Infection of B-cell lymphoma with adenovirus vector encoding CD40-ligand (CD154) induces phenotypic changes that allow for autologous immune recognition.", BLOOD, (19971115), vol. 90, no. 10, page 2280, XP002066598 [PX] 3,9,11-19,21,28,45,50,55 * the whole document * [T] 2
		[PX] - KATO, K. ET AL., "Adenovirus-mediated gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells.", BLOOD, (19971115), vol. 90, no. 10, page 1157, XP002066599 [PX] 2,3,11-19,21,28,45 * the whole document *
	Examination	WO03099340
	by applicant	- SMITH, M.M. ET AL., JOURNAL OF BIOL. CHEM., vol. 270, pages 6440 - 6449
		- NAGASE, H.; G.B. FIELDS, BIOPOLYMERS, vol. 40, pages 399 - 416
		- WONG, SEMIN. ONCOL., (1996), vol. 23, page 159
		- GLORIOSO, J. C.; N. A. DELUCA; D. J. FINK, ANNU. REV. MICROBIOL., (1995), vol. 49, page 675
		- FLOTTE, T. R.; B. J. CARTER, GENE, (1995), vol. 2, page 357
		- RANDRIANARISON-JEWTOUKOFF, V.; M. PERRICAUDET, BIOLOQICALS., (1995), vol. 23, page 145
		- KOHN, D. B., CURR. OPIN. PEDIATR., (1995), vol. 7, page 56
		- VILE, R. G.; S. J. RUSSELL, BR. MED. BULL., (1995), vol. 51, page 12
		- RUSSELL, S. J., SEMIN. CANCER BIOL., (1994), vol. 5, page 437
		- ALI, M.; N. R. LEMOINE; C. J. RING, GENE THER., (1994), vol. 1, page 367
		- OKIAMA; BERG, MOL. CELL. BIOL., (1983), vol. 3, page 280
		- KOSSMAN ET AL., NATURE, (1984), vol. 312, page 768
		- BERMAN, PROC. NATL. ACAD. SCI. USA, (1984), vol. 81, page 7176
		- DEANS ET AL., PROC. NATL. ACAD. SCI. USA, (1984), vol. 81, page 1292

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 35p